Page 1191 - Basic _ Clinical Pharmacology ( PDFDrive )

Neisseria (continued )
Healthy persons aged 19–49 years who desire protection against
influenza. May be substituted for inactivated vaccine in healthy

2–4 years with wheezing in the past year children 2–18 years except (1) asthmatics, and (2) those aged For all children Adults born after 1956 All adolescents Preferred over polysaccharide vaccine in persons aged 11–55 years College freshman aged <22 years who live in dormitories Military recruits Individuals with asplenia or complement deficiency (two-dose series) Microbiologists who are routinely exposed to isolates of meningitidis HIV-positive men who have sex with men Adult travelers >55 years to are

Yearly with current vaccine 1. None 2. 1. Every 5 years if there is continu- 2. ing high risk of 3. exposure 4. 5. 6. 7. Every 5 years if 1. there is continu- ing high risk of exposure 1. None 2. 3. 1. Repeat after 5 years in 2. patients at high risk 1. One-time booster dose for adults at 2. increased risk of exposure Serologic testing 1. every 6 months 2. to 2 years in per- sons at high risk None 1. Every 10 years 2.

Split dose in each nostril. Children age 5–8 who are receiving influ- enza vaccine for the first time should receive two doses administered 6–10 weeks apart See Table A–2 One dose One dose See Table A–2 One dose See Table A–2 for childhood schedule. Adults: Two doses 4–8 weeks apart, and a third dose 6–12 months after the second Preexposure: Three doses at days 0, 7, and 21 or 28 Postexposure: Four doses at days 0, 3, 7, and 14; immunosuppressed patients should receive a 5th dose at day 28 See Tab

Intranasal Subcutaneous Intramuscular Subcutaneous Intramuscular or subcutaneous Intramuscular or subcutaneous Subcutaneous Intramuscular Oral Intramuscular

Live virus Live virus Bacterial polysaccharides conjugated to diphtheria toxoid Bacterial polysaccharides of serotypes A/C/Y/W-135 Bacterial polysaccharides conjugated to protein Bacterial polysaccharides of 23 serotypes Inactivated viruses of all three serotypes Inactivated virus Live virus Toxoids

Influenza, live attenuated Measles- mumps-rubella (MMR) Meningococcal conjugate vaccine Meningococcal polysaccharide vaccine Pneumococcal conjugate vaccine Pneumococcal polysaccharide vaccine Poliovirus vaccine, inactivated (IPV) Rabies Rotavirus Tetanus- diphtheria (Td or DT) 5

1177